Apellis Pharmaceuticals, Inc. — Director's Dealing 2017

Nov 8, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2017-11-08

Reporting Person: Watson David O. (General Counsel)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	9376	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$2.67	2023-12-31	Common Stock (60947)		Direct
Stock Option (right to buy)	$3.76	2026-02-07	Common Stock (23441)		Direct
Stock Option (right to buy)	$4.31	2027-08-22	Common Stock (23441)		Direct

Footnotes

F1: The securities are held by The Watson Education Trust (the "Trust"), for which the reporting person serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Trust except to the extent of his pecuniary interest therein.

F2: This option was granted on January 1, 2014 and has vested as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.

F3: This option was granted on February 8, 2016 and has vested as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.

F4: This option was granted on August 21, 2017 and will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.